Averna Therapeutics, formerly known as Exsilio Therapeutics, Appoints Thomas M. Barnes, Ph.D., as Chief Executive Officer

Posted on by

Dr. Barnes brings more than 25 years of biotech leadership expertise and a proven track record in advancing transformative early-stage therapies Interim CEO Tal Zaks, M.D., Ph.D., to continue as executive chair BOSTON, Jan. 27, 2025 /PRNewswire/ — Averna Therapeutics, Inc. (“Averna”;…